[Skip to Navigation]
Research Letter
November 12, 2020

Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials

Author Affiliations
  • 1American Cancer Society Cancer Action Network, Washington, DC
  • 2Josh Bersin Academy, Oakland, California
  • 3Fred Hutchinson Cancer Research Center, Seattle, Washington
JAMA Oncol. 2021;7(1):131-132. doi:10.1001/jamaoncol.2020.5748

The coronavirus disease 2019 (COVID-19) outbreak substantially reduced cancer clinical trial accrual.1 Many sites temporarily paused enrollment owing to state, local, sponsor, or institutional restrictions intended to prevent the spread of COVID-19.2 Once site and enrollment restrictions lift, it is unclear whether patients will be as willing to participate in clinical research as before the outbreak, especially if community COVID-19 transmission is still occurring. To examine this, we surveyed a large group of cancer survivors about their attitudes toward trial participation during the COVID-19 pandemic.

First Page Preview View Large
First page PDF preview
First page PDF preview
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words